AVEO to Study Fotivda With Bristol's Opdivo in Kidney Cancer

By Colin Kellaher

AVEO Pharmaceuticals Inc. Friday said it agreed to work with Bristol Myers Squibb Co. to study AVEO's Fotivda in combination with Bristol's blockbuster cancer drug Opdivo in renal cell carcinoma, the most common type of kidney cancer.

The Boston biopharmaceutical company said it plans a phase 3 study of the combination in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.

AVEO said it will serve as the study sponsor and will be responsible for costs associated with the trial, while New York-based Bristol Myers will supply Opdivo for the study.

AVEO earlier this week said the U.S. Food and Drug Administration approved Fotivda for the treatment of adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.

AVEO shares, which closed Thursday at $11.87, rose nearly 8% in premarket trading Friday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 12, 2021 07:40 ET (12:40 GMT)

AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024